PMID- 34378405
OWN - NLM
STAT- MEDLINE
DCOM- 20220204
LR  - 20220204
IS  - 1744-8301 (Electronic)
IS  - 1479-6694 (Linking)
VI  - 17
IP  - 32
DP  - 2021 Nov
TI  - Risk factors for progression or death after first-line platinum-based 
      chemotherapy in real-world patients in the USA with ovarian cancer from 2011 to 
      2018.
PG  - 4263-4274
LID - 10.2217/fon-2021-0018 [doi]
AB  - Aim: Patient chart data from the USA during the period of January 2011 through 
      October 2018 were used to assess risk factors for progression in advanced ovarian 
      cancer after response to first-line platinum-based chemotherapy. Patients & 
      methods: Patients with stage III/IV ovarian cancer who completed first-line 
      platinum-based chemotherapy after primary or interval debulking surgery were 
      identified from the Flatiron Health database. Cox proportional hazards modeling 
      was used to assess associations between baseline factors and time to next 
      treatment (TTNT) or overall survival (OS). Results: Patients at stage IV or who 
      received interval debulking surgery had shorter TTNT and OS than patients at 
      stage III or who received primary debulking surgery, respectively. OS was worse 
      in patients with residual disease and in BRCA wild-type. Conclusion: Multiple 
      factors were associated with shorter TTNT or OS in this retrospective real-world 
      analysis.
FAU - Westin, Shannon N
AU  - Westin SN
AUID- ORCID: 0000-0002-1922-0156
AD  - Department of Gynecologic Oncology & Reproductive Medicine, University of Texas 
      MD Anderson Cancer Center, Houston, TX 77230, USA.
FAU - Louie-Gao, Melinda
AU  - Louie-Gao M
AUID- ORCID: 0000-0002-2777-5960
AD  - Department of Statistics, GlaxoSmithKline, Waltham, MA 02451, USA.
FAU - Gupta, Divya
AU  - Gupta D
AD  - Department of Clinical Development, GlaxoSmithKline, Waltham, MA 02451, USA.
FAU - Thaker, Premal H
AU  - Thaker PH
AUID- ORCID: 0000-0002-0568-6959
AD  - Department of Obstetrics & Gynecology, Division of Gynecologic Oncology, 
      Washington University School of Medicine, St Louis, MO 63110, USA.
LA  - eng
GR  - GlaxoSmithKline/
PT  - Journal Article
PT  - Observational Study
DEP - 20210811
PL  - England
TA  - Future Oncol
JT  - Future oncology (London, England)
JID - 101256629
RN  - 49DFR088MY (Platinum)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Disease Progression
MH  - Female
MH  - Genes, BRCA1
MH  - Genes, BRCA2
MH  - Humans
MH  - Middle Aged
MH  - Mutation
MH  - Ovarian Neoplasms/*drug therapy/genetics/mortality
MH  - Platinum/therapeutic use
MH  - Proportional Hazards Models
MH  - Retrospective Studies
MH  - Risk Factors
MH  - Time Factors
MH  - Young Adult
OTO - NOTNLM
OT  - epithelial ovarian carcinoma
OT  - ovarian cancer
OT  - ovarian carcinoma
OT  - prognosis
OT  - risk factors
EDAT- 2021/08/12 06:00
MHDA- 2022/02/05 06:00
CRDT- 2021/08/11 08:44
PHST- 2021/08/12 06:00 [pubmed]
PHST- 2022/02/05 06:00 [medline]
PHST- 2021/08/11 08:44 [entrez]
AID - 10.2217/fon-2021-0018 [doi]
PST - ppublish
SO  - Future Oncol. 2021 Nov;17(32):4263-4274. doi: 10.2217/fon-2021-0018. Epub 2021 
      Aug 11.